4'-IODO-4'-DEOXYDOXORUBICIN (IDX) IN COLORECTAL-CANCER - A MULTICENTER PHASE-II STUDY

Background: Iododoxorubicin is a doxorubicin analogue with a promising antineoplastic and toxicity profile in experimental systems. Patients and Methods: Patients with measurable metastatic colorectal cancer wi thout prior systemic treatment received iododoxorubicin 80 mg/m(2) int ravenously, every 3 weeks until disease progression. Results: There ha ve been no objective responses among the 18 evaluable patients. Toxici ty was generally mild, the most pronounced side effect was myelosuppre ssion. Conclusion: Iododoxorubicin is ineffective in metastatic colore ctal cancer.